Remifentanil

Overview

Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.

Indication

For use during the induction and maintenance of general anesthesia.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures	2025/06/25	NCT07035301	Not Applicable	Recruiting	Harbin Medical University
Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery	2025/06/24	NCT07033442	Not Applicable	Completed	Ataturk Training and Research Hospital
Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery	2025/05/06	NCT06958393	Phase 4	Not yet recruiting	Qianfoshan Hospital
Pain Control and Quality of Recovery After Intravenous Methadone Versus Intravenous Remifentanil in Craniotomy Surgery	2025/02/05	NCT06810336	Early Phase 1	Not yet recruiting	University of Virginia
Postoperative Cognitive Dysfunction in Transsphenoidal Pituitary Surgeries	2025/01/27	NCT06793150	Phase 4	Completed	Kocaeli University
The Impact of Low-Dose Esketamine Combined With Ciprofol on the Quality of Early Postoperative Recovery Among Elderly Patients Undergoing Painless Gastroscopy	2024/09/27	NCT06617039	Not Applicable	Active, not recruiting	Northern Jiangsu People's Hospital
Remifentanil and Remimazolam to Limit Patient Movement	2024/09/04	NCT06583811	Not Applicable	Recruiting	Egymedicalpedia
Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation	2024/08/21	NCT06564857	Phase 4	Not yet recruiting	Nordsjaellands Hospital
Efficacy of Remifentanil in Preventing Emergence Agitation	2024/08/06	NCT06539013	Not Applicable	Recruiting	Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury	2024/08/01	NCT06531837	Not Applicable	Not yet recruiting	Beijing Tiantan Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Remifentanil Hydrochloride	Fresenius Kabi USA, LLC	63323-725	INTRAVENOUS	1 mg in 1 mL	10/4/2019
Ultiva	Mylan Institutional LLC	72078-034	INTRAVENOUS	1 mg in 1 mL	4/15/2022
Ultiva	Mylan Institutional LLC	67457-912	INTRAVENOUS	1 mg in 1 mL	10/21/2019
Ultiva	Mylan Institutional LLC	67457-914	INTRAVENOUS	1 mg in 1 mL	10/21/2019
Ultiva	Mylan Institutional LLC	67457-913	INTRAVENOUS	1 mg in 1 mL	10/21/2019
Remifentanil Hydrochloride	Fresenius Kabi USA, LLC	63323-723	INTRAVENOUS	1 mg in 1 mL	10/31/2019
Ultiva	Mylan Institutional LLC	72078-035	INTRAVENOUS	1 mg in 1 mL	4/15/2022
REMIFENTANIL HYDROCHLORIDE	Hikma Pharmaceuticals USA Inc.	0143-9392	INTRAVENOUS	2 mg in 2 mL	1/1/2024
Remifentanil Hydrochloride	Fresenius Kabi USA, LLC	63323-723	INTRAVENOUS	1 mg in 1 mL	10/4/2019
Ultiva	Mylan Institutional LLC	67457-198	INTRAVENOUS	1 mg in 1 mL	6/15/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
ULTIVA FOR INJECTION 1 mg/vial	GlaxoSmithKline Manufacturing S.p.A.	SIN09542P	INJECTION, POWDER, FOR SOLUTION	1 mg/vial	11/21/1997

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
Remifentanil Hydrochloride for Injection	宜昌人福药业有限责任公司	国药准字H20030199	化学药品	注射剂	6/10/2020
Remifentanil Hydrochloride for Injection	国药集团工业有限公司廊坊分公司	国药准字H20123422	化学药品	注射剂	7/28/2022
Remifentanil Hydrochloride for Injection	宜昌人福药业有限责任公司	国药准字H20030197	化学药品	注射剂	6/10/2020
Remifentanil Hydrochloride for Injection	江苏恩华药业股份有限公司	国药准字H20143314	化学药品	注射剂	9/30/2019
Remifentanil Hydrochloride for Injection	江苏恩华药业股份有限公司	国药准字H20143315	化学药品	注射剂	9/30/2019
Remifentanil Hydrochloride for Injection	宜昌人福药业有限责任公司	国药准字H20030200	化学药品	注射剂	6/15/2022
Remifentanil Hydrochloride for Injection	国药集团工业有限公司廊坊分公司	国药准字H20123421	化学药品	注射剂	7/28/2022

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
ULTIVA FOR INJ 1MG	N/A	Aspen Pharmacare Asia Limited	N/A	N/A	7/31/1998
ULTIVA FOR INJ 2MG	N/A	Aspen Pharmacare Asia Limited	N/A	N/A	7/31/1998

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
REMIFENTANIL VIATRIS 2mg remifentanil (as hydrochloride) powder for injection vial	163902	Alphapharm Pty Ltd	Medicine	A	10/15/2012
Remifentanil-AFT, remifentanil (as hydrochloride) 1 mg, powder for injection, glass vial	193697	AFT Pharmaceuticals Pty Ltd	Medicine	A	3/20/2013
ULTIVA Remifentanil (as hydrochloride) 5mg powder for injection vial	58690	Aspen Pharmacare Australia Pty Ltd	Medicine	A	5/4/1998
GenRx Remifentanil remifentanil (as hydrochloride) 5 mg powder for injection vial	234714	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	1/6/2016
ULTIVA Remifentanil (as hydrochloride) 2mg powder for injection vial	58689	Aspen Pharmacare Australia Pty Ltd	Medicine	A	5/11/1998
ULTIVA Remifentanil (as hydrochloride) 1mg powder for injection vial	58688	Aspen Pharmacare Australia Pty Ltd	Medicine	A	5/4/1998
REMIFENTANIL VIATRIS 5mg remifentanil (as hydrochloride) powder for injection vial	163903	Alphapharm Pty Ltd	Medicine	A	10/15/2012
Remifentanil-AFT, remifentanil (as hydrochloride) 2 mg, powder for injection, glass vial	194069	AFT Pharmaceuticals Pty Ltd	Medicine	A	3/20/2013
GenRx Remifentanil remifentanil (as hydrochloride) 1 mg powder for injection vial	234711	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	1/6/2016
GenRx Remifentanil remifentanil (as hydrochloride) 2 mg powder for injection vial	234713	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	1/6/2016

Related News

HSK21542 Demonstrates Superior Efficacy in Two Phase 3 Trials for Postoperative Pain Management

2 months ago

• HSK21542, a novel kappa opioid receptor agonist, demonstrated statistically significant superiority over placebo in reducing postoperative pain intensity in two phase 3 trials involving 658 patients across 47 centers in China. • The drug showed non-inferiority to tramadol while exhibiting a markedly better safety profile, with significantly lower incidences of nausea (10.1% vs 41.9%) and vomiting (8.5% vs 38.0%) compared to tramadol. • Patients receiving HSK21542 required fewer rescue analgesics and reported higher satisfaction scores, with the drug maintaining efficacy for up to 24 hours post-administration. • The favorable safety profile included no respiratory depression events and reduced gastrointestinal side effects, positioning HSK21542 as a promising alternative to traditional opioid therapies.

Dexmedetomidine Nasal Spray Shows Promise in Reducing Emergence Agitation After ENT Surgery

9 months ago

A randomized, double-blind, placebo-controlled trial is underway to evaluate dexmedetomidine nasal spray's effectiveness in reducing emergence agitation (EA) in adults after ENT surgery.

LLNL's Subetadex Shows Promise as Novel Fentanyl Overdose Treatment

9 months ago

Lawrence Livermore National Laboratory (LLNL) researchers have discovered subetadex, a potential new treatment to counteract fentanyl and related opioid overdoses.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access